

Preconditioning

Bibliography of One Hundred Key Papers

-
- Ardell JL, Yang XM, Barron BA, Downey JM, Cohen MV.** *Endogenous myocardial norepinephrine is not essential for ischemic preconditioning in rabbit heart.*
Am J Physiol. 1996;270(3, pt 2):H-1078-H-1084.
-
- Armstrong S, Downey JM, Ganote CE.** *Preconditioning of isolated rabbit cardiomyocytes: induction by metabolic stress and blockade by the adenosine antagonist SPT and calphostin C, a protein kinase C inhibitor.*
Cardiovasc Res. 1994;28:72-77.
-
- Armstrong SC, Hoover DB, Delacey MH, Ganote CE.** *Translocation of PKC, protein phosphatase inhibition and preconditioning of rabbit cardiomyocytes.*
J Mol Cell Cardiol. 1996;28:1479-1492.
-
- Armstrong SC, Kao R, Gao W, et al.** *Comparison of in vitro preconditioning responses of isolated pig and rabbit cardiomyocytes: effects of a protein phosphatase inhibitor, fostriecin.*
J Mol Cell Cardiol. 1997;29:3009-3024.
-
- Armstrong SC, Liu GS, Downey JM, Ganote CE.** *Potassium channels and preconditioning of isolated rabbit cardiomyocytes: effects of glyburide and pinacidil.*
J Mol Cell Cardiol. 1995;27:1765-1774.
-
- Asimakis GK.** *Myocardial glycogen depletion cannot explain the cardioprotective effects of ischemic preconditioning in the rat heart.*
J Mol Cell Cardiol. 1996;28:563-570.
-
- Auchampach JA, Gross GJ.** *Adenosine A₁ receptors, K_{ATP} channels, and ischemic preconditioning in dogs.*
Am J Physiol. 1993;264(5, pt 2):H-1327-H-1336.
-
- Baines CP, Goto M, Downey JM.** *Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium.*
J Mol Cell Cardiol. 1997;29:207-216.
-
- Banerjee A, Locke-Winter C, Rogers KB, et al.** *Preconditioning against myocardial dysfunction after ischemia and reperfusion by an α_1 -adrenergic mechanism.*
Circ Res. 1993;73:656-670.
-
- Barbosa V, Sievers RE, Zaugg CE, Wolfe CL.** *Preconditioning ischemia time determines the degree of glycogen depletion and infarct size reduction in rat hearts.*
Am Heart J. 1996;131:224-230.
-
- Baxter GF, Goma FM, Yellon DM.** *Involvement of protein kinase C in the delayed cytoprotection following sublethal ischaemia in rabbit myocardium.*
Br J Pharmacol. 1995;115:222-224.
-
- Baxter GF, Goma FM, Yellon DM.** *Characterisation of the infarct-limiting effect of delayed preconditioning: time course and dose-dependency studies in rabbit myocardium.*
Basic Res Cardiol. 1997;92:159-167.
-

Bibliography of One Hundred Key Papers

- Baxter GF, Marber MS, Patel VC, Yellon DM.** Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. *Circulation.* 1994;90:2993-3000.
-
- Birnbaum Y, Hale SL, Kloner RA.** Progressive decrease in the ST segment elevation during ischemic preconditioning: is it related to recruitment of collateral vessels? *J Mol Cell Cardiol.* 1996;28:1493-1499.
-
- Bolli R, Bhatti ZA, Tang XL, et al.** Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. *Circ Res.* 1997;81:42-52.
-
- Brooks G, Hearse DJ.** Role of protein kinase C in ischemic preconditioning: player or spectator? *Circ Res.* 1996;79:627-630.
-
- Bugge E, Ytrehus K.** Bradykinin protects against infarction but does not mediate ischemic preconditioning in the isolated rat heart. *J Mol Cell Cardiol.* 1996;28:2333-2341.
-
- Cave AC.** Preconditioning induced protection against post-ischaemic contractile dysfunction: characteristics and mechanisms. *J Mol Cell Cardiol.* 1995;27:969-979.
-
- Chen W, Wetsel W, Steenbergen C, Murphy E.** Effect of ischemic preconditioning and PKC activation on acidification during ischemia in rat heart. *J Mol Cell Cardiol.* 1996;28:871-880.
-
- Cohen MV, Liu Y, Liu GS, et al.** Phospholipase D plays a role in ischemic preconditioning in rabbit heart. *Circulation.* 1996;94:1713-1718.
-
- Cohen MV, Thornton JD, Thornton CS, Sato H, Miki T, Downey JM.** Intravenous co-infusion of adenosine and norepinephrine preconditions the heart without adverse hemodynamic effects. *J Thorac Cardiovasc Surg.* 1997;114:236-242.
-
- Cohen MV, Yang XM, Downey JM.** Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning. *Circ Res.* 1994;74:998-1004.
-
- Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW Jr, Herrmann HC, Laskey WK.** Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. *Circulation.* 1990;82:2044-2051.
-
- Goto M, Cohen MV, Van Wylen DGL, Downey JM.** Attenuated purine production during subsequent ischemia in preconditioned rabbit myocardium is unrelated to the mechanism of protection. *J Mol Cell Cardiol.* 1996;28:447-454.
-
- Goto M, Liu Y, Yang XM, Ardell JL, Cohen MV, Downey JM.** Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. *Circ Res.* 1995;77:611-621.
-
- Gottlieb RA, Gruol DL, Zhu JY, Engler RL.** Preconditioning in rabbit cardiomyocytes: role of pH, vacuolar proton ATPase, and apoptosis. *J Clin Invest.* 1996;97:2391-2398.
-



-
- Gross GJ, Auchampach JA.** *Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.*
Circ Res. 1992;70:223-233.
-
- Headrick JP.** *Ischemic preconditioning: bioenergetic and metabolic changes and the role of endogenous adenosine.*
J Mol Cell Cardiol. 1996;28:1227-1240.
-
- Ikonomidis JS, Shirai T, Weisel RD, et al.** *Preconditioning cultured human pediatric myocytes requires adenosine and protein kinase C.*
Am J Physiol. 1997;272(3, pt 2):H-1220-H-1230.
-
- Jennings RB, Murry CE, Reimer KA.** *Energy metabolism in preconditioned and control myocardium: effect of total ischemia.*
J Mol Cell Cardiol. 1991;23:1449-1458.
-
- Kaszala K, Vegh A, Papp JG, Parratt JR.** *Time course of the protection against ischaemia and reperfusion-induced ventricular arrhythmias resulting from brief periods of cardiac pacing.*
J Mol Cell Cardiol. 1996;28:2085-2095.
-
- King LM, Opie LH.** *Does preconditioning act by glycogen depletion in the isolated rat heart?*
J Mol Cell Cardiol. 1996;28:2305-2321.
-
- Kitakaze M, Hori M, Morioka T, et al.** *Alpha₁-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5'-nucleotidase activity.*
J Clin Invest. 1994;93:2197-2205.
-
- Kitakaze M, Node K, Minamino T, et al.** *Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5'-nucleotidase.*
Circulation. 1996;93:781-791.
-
- Kloner RA, Shook T, Przyklenk K, et al.** *Previous angina alters in-hospital outcome in TIMI 4: a clinical correlate to preconditioning?*
Circulation. 1995;91:37-45.
-
- Kolocassides KG, Galiñanes M, Hearse DJ.** *Preconditioning accelerates contracture and ATP depletion in blood-perfused rat hearts.*
Am J Physiol. 1995;269(4, pt 2):H-1415-H-1420.
-
- Kolocassides KG, Seymour AML, Galiñanes M, Hearse DJ.** *Paradoxical effect of ischemic preconditioning on ischemic contracture? NMR studies of energy metabolism and intracellular pH in the rat heart.*
J Mol Cell Cardiol. 1996;28:1045-1057.
-
- Kuzuya T, Hoshida S, Yamashita N, et al.** *Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia.*
Circ Res. 1993;72:1293-1299.
-
- Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R.** *Preconditioning of human myocardium with adenosine during coronary angioplasty.*
Circulation. 1997;95:2500-2507.
-
- Li GC, Vasquez JA, Gallagher KP, Lucchesi BR.** *Myocardial protection with preconditioning.*
Circulation. 1990;82:609-619.
-

Bibliography of One Hundred Key Papers

- Li Y, Kloner RA.** *Does protein kinase C play a role in ischemic preconditioning in rat hearts?*
Am J Physiol. 1995;268(1, pt 2):H-426-H-431.
-
- Liu GS, Richards SC, Olsson RA, Mullane K, Walsh RS, Downey JM.** *Evidence that the adenosine A₃ receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart.*
Cardiovasc Res. 1994;28:1057-1061.
-
- Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson RA, Downey JM.** *Protection against infarction afforded by preconditioning is mediated by A₁ adenosine receptors in rabbit heart.*
Circulation. 1991;84:350-356.
-
- Liu Y, Downey JM.** *Ischemic preconditioning protects against infarction in rat heart.*
Am J Physiol. 1992;263(4, pt 2):H-1107-H-1112.
-
- Liu Y, Gao WD, O'Rourke B, Marban E.** *Synergistic modulation of ATP-sensitive K⁺ currents by protein kinase C and adenosine: implications for ischemic preconditioning.*
Circ Res. 1996;78:443-454.
-
- Liu Y, Tsuchida A, Cohen MV, Downey JM.** *Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts.*
J Mol Cell Cardiol. 1995;27:883-892.
-
- Liu Y, Ytrehus K, Downey JM.** *Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium.*
J Mol Cell Cardiol. 1994;26:661-668.
-
- Marber MS, Latchman DS, Walker JM, Yellon DM.** *Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction.*
Circulation. 1993;88:1264-1272.
-
- Matsuda M, Catena TG, Vander Heide RS, Jennings RB, Reimer KA.** *Cardiac protection by ischaemic preconditioning is not mediated by myocardial stunning.*
Cardiovasc Res. 1993;27:585-592.
-
- Maulik N, Watanabe M, Zu YL, et al.** *Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase 2 in rat hearts.*
FEBS Lett. 1996;396:233-237.
-
- Mitchell MB, Meng X, Ao L, Brown JM, Harken AH, Banerjee A.** *Preconditioning of isolated rat heart is mediated by protein kinase C.*
Circ Res. 1995;76:73-81.
-
- Miura T, Adachi T, Ogawa T, Iwamoto T, Tsuchida A, Iimura O.** *Myocardial infarct size-limiting effect of ischemic preconditioning: its natural decay and the effect of repetitive preconditioning.*
Cardiovasc Pathol. 1992;1:147-154.
-
- Miura T, Goto M, Urabe K, Endoh A, Shimamoto K, Iimura O.** *Does myocardial stunning contribute to infarct size limitation by ischemic preconditioning?*
Circulation. 1991;84:2504-2512.
-
- Miyawaki H, Ashraf M.** *Ca²⁺ as a mediator of ischemic preconditioning.*
Circ Res. 1997;80:790-799.
-
- Miyawaki H, Zhou X, Ashraf M.** *Calcium preconditioning elicits strong protection against ischemic injury via protein kinase C signaling pathway.*
Circ Res. 1996;79:137-146.
-



-
- Moolman JA, Genade S, Tromp E, Lochner A.** *A comparison between ischemic preconditioning and anti-adrenergic interventions: cAMP, energy metabolism and functional recovery.* **Basic Res Cardiol.** 1996;91:219-233.
-
- Morita Y, Murakami T, Iwase T, et al.** *K_{ATP} channels contribute to the cardioprotection of preconditioning independent of anaesthetics in rabbit hearts.* **J Mol Cell Cardiol.** 1997;29:1267-1276.
-
- Murphy E, Glasgow W, Fralix T, Steenbergen C.** *Role of lipoxygenase metabolites in ischemic preconditioning.* **Circ Res.** 1995;76:457-467.
-
- Murry CE, Jennings RB, Reimer KA.** *Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.* **Circulation.** 1986;74:1124-1136.
-
- Murry CE, Richard VJ, Jennings RB, Reimer KA.** *Myocardial protection is lost before contractile function recovers from ischemic preconditioning.* **Am J Physiol.** 1991;260(3, pt 2):H-796-H-804.
-
- Murry CE, Richard VJ, Reimer KA, Jennings RB.** *Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode.* **Circ Res.** 1990;66:913-931.
-
- Nakagawa Y, Ito H, Kitakaze M, et al.** *Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: retrospective clinical evidence of "preconditioning."* **J Am Coll Cardiol.** 1995;25:1076-1083.
-
- Niroomand F, Weinbrenner C, Weis A, et al.** *Impaired function of inhibitory G proteins during acute myocardial ischemia of canine hearts and its reversal during reperfusion and a second period of ischemia: possible implications for the protective mechanism of ischemic preconditioning.* **Circ Res.** 1995;76:861-870.
-
- Ottani F, Galvani M, Ferrini D, et al.** *Prodromal angina limits infarct size: a role for ischemic preconditioning.* **Circulation.** 1995;91:291-297.
-
- Ovize M, Kloner RA, Przyklenk K.** *Stretch preconditions canine myocardium.* **Am J Physiol.** 1994;266(1, pt 2):H-137-H-146.
-
- Ovize M, Przyklenk K, Hale SL, Kloner RA.** *Preconditioning does not attenuate myocardial stunning.* **Circulation.** 1992;85:2247-2254.
-
- Ping P, Zhang J, Qiu Y, et al.** *Ischemic preconditioning induces selective translocation of protein kinase C isoforms ϵ and η in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity.* **Circ Res.** 1997;81:404-414.
-
- Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P.** *Regional ischemic "preconditioning" protects remote virgin myocardium from subsequent sustained coronary occlusion.* **Circulation.** 1993;87:893-899.
-
- Przyklenk K, Sussman MA, Simkhovich BZ, Kloner RA.** *Does ischemic preconditioning trigger translocation of protein kinase C in the canine model?* **Circulation.** 1995;92:1546-1557.
-

Bibliography of One Hundred Key Papers

- Qiu Y, Tang XL, Park SW, Sun JZ, Kalya A, Bolli R.** *The early and late phases of ischemic preconditioning: a comparative analysis of their effects on infarct size, myocardial stunning, and arrhythmias in conscious pigs undergoing a 40-minute coronary occlusion.*
Circ Res. 1997;80:730-742.
-
- Ramasamy R, Liu H, Anderson S, Lundmark J, Schaefer S.** *Ischemic preconditioning stimulates sodium and proton transport in isolated rat hearts.*
J Clin Invest. 1995;96:1464-1472.
-
- Sandhu R, Thomas U, Diaz RJ, Wilson GJ.** *Effect of ischemic preconditioning of the myocardium on cAMP.*
Circ Res. 1996;78:137-147.
-
- Schott RJ, Rohmann S, Braun ER, Schaper W.** *Ischemic preconditioning reduces infarct size in swine myocardium.*
Circ Res. 1990;66:1133-1142.
-
- Schultz JEJ, Hsu AK, Gross GJ.** *Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart.*
Circ Res. 1996;78:1100-1104.
-
- Schultz JEJ, Hsu AK, Gross GJ.** *Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart.*
J Mol Cell Cardiol. 1997;29:1355-1362.
-
- Schultz JEJ, Qian YZ, Gross GJ, Kukreja RC.** *The ischemia-selective K_{ATP} channel antagonist, 5-hydroxydecanoate, blocks ischemic preconditioning in the rat heart.*
J Mol Cell Cardiol. 1997;29:1055-1060.
-
- Schulz R, Rose J, Heusch G.** *Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine.*
Am J Physiol. 1994;267(4, pt 2):H-1341-H-1352.
-
- Schulz R, Rose J, Post H, Heusch G.** *Involvement of endogenous adenosine in ischaemic preconditioning in swine.*
Pflügers Arch. 1995;430:273-282.
-
- Shattock MJ, Lawson CS, Hearse DJ, Downey JM.** *Electrophysiological characteristics of repetitive ischemic preconditioning in the pig heart.*
J Mol Cell Cardiol. 1996;28:1339-1347.
-
- Shiki K, Hearse DJ.** *Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias.*
Am J Physiol. 1987;253(6, pt 2):H-1470-H-1476.
-
- Silva PH, Dillon D, Van Wylen DGL.** *Adenosine deaminase inhibition augments interstitial adenosine but does not attenuate myocardial infarction.*
Cardiovasc Res. 1995;29:616-623.
-
- Simkhovich BZ, Przyklenk K, Hale SL, Patterson M, Kloner RA.** *Direct evidence that ischemic preconditioning does not cause protein kinase C translocation in rabbit heart.*
Cardiovasc Res. 1996;32:1064-1070.
-
- Speechly-Dick ME, Grover GJ, Yellon DM.** *Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K^+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model.*
Circ Res. 1995;77:1030-1035.
-



-
- Speechly-Dick ME, Mocanu MM, Yellon DM.** *Protein kinase C: its role in ischemic preconditioning in the rat.* **Circ Res.** 1994;75:586-590.
-
- Tanaka M, Fujiwara H, Yamasaki K, et al.** *Ischemic preconditioning elevates cardiac stress protein but does not limit infarct size 24 or 48 h later in rabbits.* **Am J Physiol.** 1994;267(4, pt 2):H-1476-H-1482.
-
- Tang XL, Qiu Y, Park SW, Sun JZ, Kalya A, Bolli R.** *Time course of late preconditioning against myocardial stunning in conscious pigs.* **Circ Res.** 1996;79:424-434.
-
- Thornton J, Striplin S, Liu GS, et al.** *Inhibition of protein synthesis does not block myocardial protection afforded by preconditioning.* **Am J Physiol.** 1990;259(6, pt 2):H-1822-H-1825.
-
- Thornton JD, Thornton CS, Downey JM.** *Effect of adenosine receptor blockade: preventing protective preconditioning depends on time of initiation.* **Am J Physiol.** 1993;265(2, pt 2):H-504-H-508.
-
- Tomai F, Crea F, Gaspardone A, et al.** *Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K⁺ channel blocker.* **Circulation.** 1994;90:700-705.
-
- Tomai F, Crea F, Gaspardone A, et al.** *Effects of A₁ adenosine receptor blockade by bamiphylline on ischaemic preconditioning during coronary angioplasty.* **Eur Heart J.** 1996;17:846-853.
-
- Tritto I, D'Andrea D, Eramo N, et al.** *Oxygen radicals can induce preconditioning in rabbit hearts.* **Circ Res.** 1997;80:743-748.
-
- Tsuchida A, Liu Y, Liu GS, Cohen MV, Downey JM.** *α₁-Adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C.* **Circ Res.** 1994;75:576-585.
-
- Tsuchida A, Thompson R, Olsson RA, Downey JM.** *The anti-infarct effect of an adenosine A₁-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart.* **J Mol Cell Cardiol.** 1994;26:303-311.
-
- Turrens JF, Thornton J, Barnard ML, Snyder S, Liu G, Downey JM.** *Protection from reperfusion injury by preconditioning hearts does not involve increased antioxidant defenses.* **Am J Physiol.** 1992;262(2, pt 2):H-585-H-589.
-
- Vahlhaus C, Schulz R, Post H, Onallah R, Heusch G.** *No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine.* **Circ Res.** 1996;79:407-414.
-
- Van Winkle DM, Thornton JD, Downey DM, Downey JM.** *The natural history of preconditioning: cardioprotection depends on duration of transient ischemia and time to subsequent ischemia.* **Cor Art Dis.** 1991;2:613-619.
-
- Van Wylene DGL.** *Effect of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia.* **Circulation.** 1994;89:2283-2289.
-

Bibliography of One Hundred Key Papers

- Vegh A, Papp JG, Parratt J.** *Attenuation of the antiarrhythmic effects of ischaemic preconditioning by blockade of bradykinin B₂ receptors.* **Br J Pharmacol.** 1994;113:1167-1172.
-
- Vegh A, Papp JG, Szekeres L, Parratt JR.** *Are ATP sensitive potassium channels involved in the pronounced antiarrhythmic effects of preconditioning?* **Cardiovasc Res.** 1993;27:638-643.
-
- Vogt AM, Htun P, Arras M, Podzuweit T, Schaper W.** *Intramyocardial infusion of tool drugs for the study of molecular mechanisms in ischemic preconditioning.* **Basic Res Cardiol.** 1996;91:389-400.
-
- Wang P, Gallagher KP, Downey JM, Cohen MV.** *Pretreatment with endothelin-1 mimics ischemic preconditioning against infarction in isolated rabbit heart.* **J Mol Cell Cardiol.** 1996;28:579-588.
-
- Weinbrenner C, Liu GS, Cohen MV, Downey JM.** *Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart.* **J Mol Cell Cardiol.** 1997;29:2383-2391.
-
- Weinbrenner C, Wang P, Downey JM.** *Loss of glycogen during preconditioning is not a prerequisite for protection of the rabbit heart.* **Basic Res Cardiol.** 1996;91:374-381.
-
- Weselcouch EO, Baird AJ, Sleph P, Grover GJ.** *Inhibition of nitric oxide synthesis does not affect ischemic preconditioning in isolated perfused rat hearts.* **Am J Physiol.** 1995;268(1, pt 2):H-242-H-249.
-
- Wolfe CL, Sievers RE, Visseren FLJ, Donnelly TJ.** *Loss of myocardial protection after preconditioning correlates with the time course of glycogen recovery within the preconditioned segment.* **Circulation.** 1993;87:881-892.
-
- Yang XM, Baxter GF, Heads RJ, Yellon DM, Downey JM, Cohen MV.** *Infarct limitation of the second window of protection in a conscious rabbit model.* **Cardiovasc Res.** 1996;31:777-783.
-
- Yang XM, Sato H, Downey JM, Cohen MV.** *Protection of ischemic preconditioning is dependent upon a critical timing sequence of protein kinase C activation.* **J Mol Cell Cardiol.** 1997;29:991-999.
-
- Yellon DM, Alkhulaifi AM, Pugsley WB.** *Preconditioning the human myocardium.* **Lancet.** 1993;342:276-277.
-
- Ytrehus K, Liu Y, Downey JM.** *Preconditioning protects ischemic rabbit heart by protein kinase C activation.* **Am J Physiol.** 1994;266(3, pt 2):H-1145-H-1152.
-
- Zu YL, Ai Y, Gilchrist A, et al.** *High expression and activation of MAP kinase-activated protein kinase 2 in cardiac muscle cells.* **J Mol Cell Cardiol.** 1997;29:2159-2168.
-

Instructions for authors

GENERAL INSTRUCTIONS

- Manuscripts should be provided on word-processor disks (3.5-in, for IBM, IBM-compatible, or Apple computers) with three hard copies (text and figures) printed on one side of standard-sized white bond paper, double-spaced, with 2.5-cm margins. Pages must be numbered. **Standard typed page = 25 lines of 75 characters (including spaces) double-spaced, 2.5-cm margins = a total of 275 words per page.**
- All texts should be submitted in **English**. In the case of translations, the text in the original language should be included.
- On the **title page**, provide title of manuscript (title should be concise, not exceeding 120 characters, including spaces), short running title, keywords, and acknowledgments, as well as full names (first name, middle name(s), and last name) with highest academic degrees (in country-of-origin language), affiliations/address, telephone No., fax No., and E-mail address.
- **Illustrations** (photographs, tables, graphs, figures—hard copies and on disk, where possible) should be of good quality or professionally prepared, numbered according to their order, with proper orientation indicated (eg, “top,” or “left”), and **SHORT legends** provided, not repetitive of text. As figures and graphs may need to be reduced or enlarged, all absolute values and statistics should be provided. All illustrations should be cited in the text, with distinct numbering for figures and tables. Illustrations will be reproduced in full color only when clearly necessary, eg, images from nuclear medicine or histology.
- Include **HEADINGS** using a consistent style for the various levels of headings, to highlight key points and facilitate comprehension of the text. The Publisher reserves the right to add or delete headings when necessary.
- **Indent first line of each new paragraph.**
- **Abbreviations** should be used sparingly and expanded at first mention.
- Use **Systeme International (SI)** units.
- Use **generic names of drugs**.
- All **references** should be cited in the text and numbered consecutively using superscript arabic numerals. The author-date system of citation is **NOT** acceptable. “In press” references are to be avoided. In the bibliography, titles of journals should be abbreviated according to the **Index Medicus**. All authors should be listed up to six; if there are more, only the first three should be listed, followed by “et al” (*Uniform requirements for manuscripts submitted to biomedical journals “the Vancouver style.” Br Med J Clin Res. 1982;284:1766-1770*). Where necessary, references will be styled to *Dialogues in Cardiovascular Medicine* copyediting requirements. Authors bear total responsibility for the accuracy and completeness of all references and for correct text citation. Example of style for references:
 1. Ouriel K, Geary K, Green RM, Geary JE, DeWeese JA. Factors determining survival after ruptured abdominal aneurysm. *J Vasc Surg.* 1990;11:493-496.
 2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms: the case for early resection. *Circulation.* 1977;56(suppl II):II-161-II-164.
 3. Schulman JL. Immunology of influenza. In: Kilbourne ED, Alfade RT, eds. *The Influenza Viruses and Influenza*. Orlando, Fla: Academic Press Inc; 1975:373-393.
- **Copyediting:** all contributions to *Dialogues in Cardiovascular Medicine* will be styled by the Publisher's editorial dept according to the specifications of the current edition of the **American Medical Association Manual of Style, Williams & Wilkins**. Page proofs will be sent to authors for approval and should be returned within 5 days. If this time is exceeded, changes made by the editorial dept will be assumed to be accepted by the author. Authors are responsible for all statements made in their work, including changes made by the editorial dept and authorized by the author. The Publisher will edit Editorials, Abstracts, and Seminal Paper Summaries to required size if their length does not comply with specific requirements.

- **Copyright** of articles will be transferred to the Publisher of *Dialogues in Cardiovascular Medicine*. For reproduction of existing work, it is the author's responsibility to obtain copyright from the author(s) (including self) and the publisher(s) and provide copies of these authorizations with the manuscript.

EDITORIAL

The editorial should not exceed 2 standard typed pages (maximum 600 words).

LEAD ARTICLE

The lead article should not exceed 25 standard typed pages (maximum 8000 words), including an abstract of no more than 200 words, no more than 20 references, and a maximum of 10 illustrations (figures and tables). Illustrations correspond to approximately 2/3 of a standard typed page or 200 words and are counted as part of the maximum allowed 25 standard typed pages. A maximum of 5-10 keywords should be included.

RESPONDENT ARTICLES

Respondent articles should not exceed 10 standard typed pages (maximum 2500 words), including an abstract of no more than 125 words, no more than 10 references, and a maximum of 3 illustrations (figures and tables). Illustrations correspond to approximately 2/3 of a standard typed page or 200 words and are counted as part of the maximum allowed 10 standard typed pages. A maximum of 5-10 keywords should be included.

SEMINAL PAPER SUMMARIES

Seminal paper summaries take up one page of *Dialogues in Cardiovascular Medicine*: the length of each summary should **IMPERATIVELY** be comprised between 500 and 600 words, ie, **not exceed 3000 characters**. Summaries that are too short or too long will be edited by the Publisher. No figures, tables or references should be included in seminal paper summaries.